Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients with activating EGFR Mutations - POSITHES

Study identifier:D5161R00017

ClinicalTrials.gov identifier:NCT05103605

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

Positioning, utilization and effectiveness of osimertinib in first line in real-life therapeutic strategy in France Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients with activating EGFR Mutations

Medical condition

Non Small Cell Lung Cancer

Phase

N/A

Healthy volunteers

No

Study drug

Osimertinib

Sex

All

Actual Enrollment

274

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 12 May 2021
Estimated Primary Completion Date: 15 Jan 2026
Estimated Study Completion Date: 15 Jan 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria